Jh. Kim et al., IN-VITRO AND IN-VIVO ANTIBACTERIAL EFFICACIES OF CFC-222, A NEW FLUOROQUINOLONE, Antimicrobial agents and chemotherapy, 41(10), 1997, pp. 2209-2213
CFC-222 is a novel fluoroquinolone containing a C-7 bicyclic amine moi
ety with potent antibacterial activities against gram-positive, gram n
egative, and anaerobic organisms, We compared the in vitro and in vivo
activities of CFC-222 with those of ciprofloxacin, ofloxacin, and lom
efloxacin. CFC-222 was more active than the other fluoroquinolones tes
ted against gram-positive bacteria, CFC-222 was particularly active ag
ainst Streptococcus pneumoniae (MIC at which 90% of isolates are inhib
ited [MIC90], 0.2 mu g/ml), Staphylococcus aureus (MIC90, 0.2 mu g/ml
for ciprofloxacin-susceptible strains), and Enterococcus faecalis (MIC
90, 0.39 mu g/ml). Against Escherichia coli and other members of the f
amily Enterobacteriaceae, CFC-222 was slightly less active than ciprof
loxacin (MIC(90)s for E. coli, 0.1 and 0.025 mu g/ml, respectively), T
he in vitro activity of CFC-222 was not influenced by inoculum size, m
edium composition, or the presence of horse serum, However, its activi
ty was decreased significantly by a change in the pH of the medium fro
m 7.0 to 6.0, as was the case for the other quinolones tested, The in
vivo protective efficacy of CFC-222 by oral administration was greater
than those of the other quinolones tested in a mouse model of intrape
ritoneally inoculated systemic infection caused by S. aureus, CFC-222
exhibited efficacy comparable to that of ciprofloxacin in the same mod
el of infection caused by gram-negative organisms, such as E. coli and
Klebsiella pneumoniae. In this infection model, CFC-222 was slightly
less active than ciprofloxacin against Pseudomonas aeruginosa. These r
esults suggest that CPC-222 may be a promising therapeutic agent in va
rious bacterial infections.